Designing drug trials for Alzheimer’s disease: What we have learned from the release of the phase III antibody trials: A report from the EU/US/CTAD Task Force

By Bruno Vellas, Maria C. Carrillo, Cristina Sampaio, H. Robert Brashear, Eric Siemers, Harald Hampel, Lon S. Schneider, Michael Weiner, Rachelle Doody, Zaven Khachaturian, Jesse Cedarbaum, Michael Grundman, Karl Broich, Ezio Giacobini, Bruno Dubois, Reisa Sperling, Gordon K. Wilcock, Nick Fox, Philip Scheltens, Jacques Touchon, Suzanne Hendrix, Sandrine Andrieu, Paul Aisen, EU/US/CTAD Task Force Members Abstract: An international task force of investigators from academia, industry, nonprofit foundations, and regulatory agencies met in Monte Carlo, Monaco, on October 31, 2012, to review lessons learned from the recent bapineuzumab and solanezumab trials, and to incorporate insights gained from these trials into future clinical studies. Although there is Read & Research Alzheimer’s More

Leave a Reply